Vitamin D Analogs
Authors:
- 1 January 2002
- journal article
- Published by Springer Nature in Treatments in Endocrinology
- Vol. 1 (5) , 313-327
Abstract
Patients with chronic renal failure frequently develop secondary hyperparathyroidism, primarily as a result of phosphate retention and low serum 1,25(OH)2D3. Replacement therapy with calcitriol or its synthetic precursor alfacalcidol [1α(OH)D3] often produces hypercalcemia, especially when combined with calcium-based phosphate binders. In addition, the natural vitamin D compounds can exacerbate the hyperphosphatemia in patients with chronic renal failure. This combined increase in calcium and phosphate has been correlated with vascular calcification leading to coronary artery disease, the most common cause of mortality in renal patients. Several vitamin D analogs have now been developed that retain the direct suppressive action of calcitriol on the parathyroid glands but have less calcemic activity, thereby offering a safer and more effective means of controlling secondary hyperparathyroidism. Maxacalcitol [22-oxa-1,25(OH)2D3] and falecalcitriol [1,25(OH)2-26,27-F6-D3] are currently available in Japan, and paricalcitol [19-nor-1,25(OH)2D2] and doxercalciferol [1α(OH)D2] are available in the US. The mechanisms by which these analogs exert their selective actions on the parathyroid glands are under investigation. The low calcemic activity of maxacalcitol has been attributed to its rapid clearance from the circulation. This prevents sustained effects on intestinal calcium absorption and bone resorption, but still allows a prolonged suppression of parathyroid hormone gene expression. The selectivity of the other analogs is achieved by distinct mechanisms. Understanding how these compounds exert their selective actions on the parathyroid glands will aid in the design of safer, more effective analogs.Keywords
This publication has 75 references indexed in Scilit:
- A Conserved cis-Acting Element in the Parathyroid Hormone 3′-Untranslated Region Is Sufficient for Regulation of RNA Stability by Calcium and PhosphateJournal of Biological Chemistry, 2001
- 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritisKidney International, 1999
- Effective suppression of parathyroid hormone by 1α-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidismKidney International, 1997
- Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failureAmerican Journal of Kidney Diseases, 1996
- Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitroJournal of Bone and Mineral Research, 1996
- Bone Mineral Density Evaluated by Dual-Energy X-Ray Absorptiometry after One-Year Treatment with Calcitriol Started in the Predialysis Phase of Chronic Renal FailureNephron, 1995
- 1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trialKidney International, 1989
- Reduced Binding of [3H]l,25-Dihydroxyvitamin D3in the Parathyroid Glands of Patients with Renal FailureNew England Journal of Medicine, 1987
- Synthetic studies of vitamin D3 analogues. VIII Synthesis of 22-oxavitamin D3 analogues.Chemical and Pharmaceutical Bulletin, 1986
- Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.Journal of Clinical Investigation, 1984